Hyperion DeFi Inc. (HYPD) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Hyperion DeFi Inc. (NASDAQ: HYPD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $3.51 (+16.83% 1D, market cap $54.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPD ranks #299 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HYPD carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 62.7%, and ROIC of -35.0%. By comparison, HOWL (Werewolf Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M) and PLRX (Pliant Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $53.3M). Among the 5-stock peer group, HYPD leads on earnings multiple (N/A) while HYPD leads on capital efficiency (-35.0% ROIC).
Per HYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001682639), Hyperion DeFi Inc. generated $813.5K in revenue (+1318.8% YoY), -$45.3M in net income, and -$14.8M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While HYPD currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.43) and Max Pain ($3.69) forces dealer call-delta covering toward $6.80.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Hyperion DeFi Inc. (HYPD) surged +16.83% to $3.51, trading at 28% of its 52-week range ($2.34 – $6.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc Health
Elon Musk calls Hyperliquid’s ICE deal “interesting,” extending HYPE’s rally to 17% after Stan Druckenmiller’s public backing.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HYPD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HYPD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Hyperion DeFi Inc. (HYPD) ranks #299 by composite RQD confidence (50/100, grade D) and #738 by equity capitalization ($54.1M). Within this direct 5-issuer industry benchmark cohort, HYPD leads on earnings valuation at N/A trailing P/E, while HYPD leads on capital efficiency and profitability with -35.0% ROIC and 62.7% gross margin. HYPD currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HYPD
ACTIVE
Hyperion DeFi Inc. | D | 50/100 | — | 62.7% | -35.0% | +16.83% | $54.1M | Benchmark Subject |
| HOWL Werewolf Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +3.77% | $53.5M | /howl-vs-hypd → |
| PLRX Pliant Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -3.35% | $53.3M | /plrx-vs-hypd → |
| CLNN Clene Inc. | E | 34/100 | — | 78.5% | -35.0% | -3.23% | $55.4M | /clnn-vs-hypd → |
| TLPH Talphera Inc. | D- | 42/100 | — | — | -35.0% | -1.83% | $55.5M | /tlph-vs-hypd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperion DeFi Inc. (HYPD) reported GAAP revenue of $813.5K (+1318.8% vs. FY2024 revenue of $57.3K , and +21380.2% cumulative change since FY2023) , GAAP net income of -$45.3M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (+51.2% YoY). On the balance sheet, HYPD closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $813.5K | -$45.3M | -$14.8M | -$14.8M | $51.8M | — |
| FY2024 (FY) | 2024-12-31 | $57.3K | -$49.8M | -$30.1M | -$30.3M | $3.7M | — |
| FY2023 (FY) | 2023-12-31 | $3.8K | -$27.3M | -$23.8M | -$23.8M | — | — |
As of 2026-11-02, Hyperion DeFi Inc. (NASDAQ: HYPD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $3.51 (+16.83% 1D, market cap $54.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPD ranks #299 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HYPD carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 62.7%, and ROIC of -35.0%. By comparison, HOWL (Werewolf Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $53.5M) and PLRX (Pliant Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $53.3M). Among the 5-stock peer group, HYPD leads on earnings multiple (N/A) while HYPD leads on capital efficiency (-35.0% ROIC).
Per HYPD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001682639), Hyperion DeFi Inc. generated $813.5K in revenue (+1318.8% YoY), -$45.3M in net income, and -$14.8M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
HYPD last traded at $3.51 (+16.83% on volume of 547,026 shares), positioning the stock +2.33% above its 50-day simple moving average ($3.43) and +4.46% above its 200-day simple moving average ($3.36). Across its 52-week range of $2.34 to $6.48, HYPD sits at the 28.3% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.07 to $3.95).
Why HYPD Stock surged +16.83% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).